Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06614231
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-12
Brief Title:
Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIAN2 Non-small Cell Lung Cancer
Sponsor:
Organization:
None